



| DATE       | STOCK      | RECOMD | ENTRY PRICE | TARGET | STOP LOSS |
|------------|------------|--------|-------------|--------|-----------|
| 19.11.2018 | ABCAPITAL  | BUY    | 113         | 123    | 107       |
| 19.11.2018 | APOLLOTYRE | BUY    | 225         | 245    | 212       |
| 19.11.2018 | GRUH       | BUY    | 305         | 330    | 290       |

**NOTE –Stop Loss are on Daily closing basis.**

**TECHNICAL OUTLOOK**

NIFTY WEEKLY CLOSE – 10682.20 (↑ 97 pts)

Last week, Nifty began on a weak note and moved lower to 10440. However, as mentioned in our earlier report, this level acted as a support, and Nifty recovered to move up and close the week at 10682 with a gain of 97 points.

Nifty is now placed very close to its key averages on daily as well as weekly charts. It is above 13-day EMA and 55-week and 200-week EMA. The daily as well as weekly RSI is above the average.

Going ahead, the 200-day EMA near 10700 remains a strong resistance for Nifty. A move above this would take Nifty towards 10800-10850. On the other hand, Nifty could take immediate support near 10600 and 10450.





**WEEKLY INVESTMENT IDEAS REVIEW**

| DATE       | STOCK      | RECOMD | ENTRY PRICE | TARGET | STOP LOSS | TODAY CLOSE | NET % CHANGE | REMARK        |
|------------|------------|--------|-------------|--------|-----------|-------------|--------------|---------------|
| 12.11.2018 | ASIANPAINT | BUY    | 1290        | 1375   | 1245      | 1321.3      | 2.37         | Exit          |
| 12.11.2018 | GLENMARK   | BUY    | 674         | 710    | 654       | 646.95      | -4.18        | Stop loss hit |
| 12.11.2018 | KARURVYSYA | BUY    | 82          | 90     | 78        | 82.45       | 0.55         | Exit          |

**WEEKLY MARKET REVIEW**

**Sensex, Nifty log small gains**

Indian equity indices settled with small gains in the recently concluded week helped by recent weakness in crude oil prices and firmness in rupee against the US dollar. The Sensex regained the psychological 35,000 level after falling below that level at onset of the trading week. The benchmarks rose for third week in a row.

In the foreign exchange market, the rupee edged higher against the dollar. The partially convertible rupee was hovering at 71.85, compared with its close of 71.975 during the previous trading session.

In global commodities markets, Brent crude oil futures edged higher. Brent for January 2019 settlement was up 89 cents at \$67.51 a barrel.

In the week ended Friday, 16 November 2018, the Sensex gained 298.61 points or 0.84% to settle at 35,457.16. The Nifty 50 index gained 97 points or 0.91% to settle at 10,682.20. The BSE Mid-Cap index rose 53.61 points or 0.35% to settle at 14,997.81. The BSE Small-Cap index fell 185.97 points or 1.26% to settle at 14,485.88.

Index heavyweight Reliance Industries rose 3.12% at Rs 1,127.50.

Tata Motors lost 8.18%. Tata Motors Group global wholesales in October 2018, including Jaguar Land Rover, were at 1,09,597 units, higher by 6%, as compared to October 2017. Jaguar Land Rover reported 4.6% decline in total retail sales.

Eicher Motors gained 9.85%. Consolidated net profit rose 5.93% to Rs 548.76 crore on 12.68% rise in total

income to Rs 2579.29 crore in Q2 September 2018 over Q2 September 2017.

Coal India fell 1.77%. Consolidated net profit jumped 732.73% to Rs 3084.70 crore on 26.28% rise in total income to Rs 24209.33 crore in Q2 September 2018 over Q2 September 2017.

Mahindra & Mahindra fell 3.68%. Combined profit from ordinary activities after tax (after EI) rose 26% to Rs 1779 crore in Q2 September 2018 over Q2 September 2017.

Infosys fell 1.66%. The board of directors appointed Jayesh Sanghrajka as the interim Chief Financial Officer (CFO) and Key Managerial Personnel of the Company with effect from 17 November 2018. The board is in the process of selecting the next CFO. Jayesh Sanghrajka has spent 13 years in Infosys over two stints and has performed various leadership roles in the finance function.

Sun Pharmaceutical Industries fell 12.8%. The company reported consolidated net loss of Rs 108.84 crore in Q2 September 2018 as compared to net profit of Rs 1001.79 crore in Q2 September 2017. Total income rose 5.56% to Rs 7288.78 crore. Adjusted net profit for Q2 September 2018 was at Rs 996 crore with resulting adjusted net profit margin at 14.5%. After accounting for the provision of Rs 1214 crore for the estimated settlement amount payable to all the remaining plaintiffs related to the Modafinil antitrust litigation in the US, the net loss for the quarter was at Rs 219 crore.

Source: [www.capitalmarket.com](http://www.capitalmarket.com)



### SAJAG SECURITIES PVT. LTD.

MEMBER: NATIONAL STOCK EXCHANGE OF INDIA LTD.

MEMBER: BOMBAY STOCK EXCHANGE LTD.

DEPOSITORY PARTICIPANT: NATIONAL SECURITIES DEPOSITORY LTD.

DEPOSITORY PARTICIPANT: CENTRAL DEPOSITORY SERVICES LTD.

33/15 - B, KARVE ROAD, REGENT CHAMBERS, PUNE - 411004, TEL: 91-20-66014737, FAX: 91-20-25302555

email : [business@sajag.co.in](mailto:business@sajag.co.in) / [investorgrievance@sajag.co.in](mailto:investorgrievance@sajag.co.in)

NSE TM ID - 07549

BSE TM ID - 3105

NSDL DP ID: IN303647

SEBI Regn. No. INB 230754937

SEBI Regn. No. INB 010754936

CDSL DP ID : 12062400

**Disclosure:** This report is issued by Sajag Securities Pvt. Ltd. (SSPL), a stock broking company, which is regulated by SEBI and its research activities are as per SEBI Guidelines for Research Analysts December 2014. Registration Number: INH000001923. This report is prepared and distributed by SSPL for information purpose only. SSPL and the research analyst(s) who prepared this report do not have any long or short positions in derivatives markets in any of the above mentioned securities. SSPL or the research analyst(s) do not have ownership of 1% or more in the company. The research analyst(s) who prepared this research report hereby certifies that the views expressed in this research report accurately reflect the research analyst's personal views about all of the subject issuers and/or securities, that the analyst(s) have no known material conflict of interest and no part of the research analyst's compensation was, is or will be, directly or indirectly, related to the specific views or recommendations contained in this research report.

**Disclaimer:** Neither the information contained herein nor any opinion expressed should be construed or deemed to be construed as solicitation or as offering advice for the purposes of the purchase or sale of any security or investment or derivatives. The information and opinions contained in the report were considered by SSPL to be valid when published. The report also contains information provided to SSPL by third parties. The source of such information will usually be disclosed in the report. While SSPL has taken all responsible steps to ensure that this information is correct, SSPL does not offer any warranty as to the accuracy or completeness of such information. Any person placing reliance on the report to undertake trading does so entirely at his/her own risk and SSPL does not accept any liability as a result. Securities and Derivatives markets may be subject to rapid and unexpected price movements and past performance is not necessarily a guide to future performance. The report does not have regard to the specific investment objective, financial situation and the particular needs of any specific person who may receive this report. Investor must undertake independent analysis with their own legal, tax and financial advisors and reach their own decision regarding the appropriateness of investing in any securities or investment strategies discussed and recommended in this report and should understand that statements regarding future prospects may not be realized. In no circumstances be it used or considered as an offer to sell or a solicitation of any offer to buy or sell the securities mentioned in it. The information contained in the research reports may have been taken from trade and statistical services and other sources, which we believe reliable. SSPL does not guarantee that such information is accurate or complete and it should not be relied upon as such. Any opinions expressed reflect judgments at this date and are subject to change without notice. The target prices mentioned in the report are based on certain assumptions as of the date appearing in the material and may be subject to change from time to time without notice.